Phase 2 N=233 Biopsychosocial Influence on Shoulder Pain
Shoulder Pain
Primary: Number of Participants Who Met the Recovery Criterion for Shoulder Pain Intensity — 39; 32; 32; 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine — 153; 129 nanograms per milliliter (ng/mL)
N/A N=43 Mindful Breathing and tDCS for Depression
Depression · Depressive Disorder
Primary: Change in DLPFC Connectivity: Amygdala — 0.0977; -0.057 r-value
N/A N=708 Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice
Chronic Venous Disease
Primary: Dynamics of the Main Veno-specific Symptoms, Assessed by Visual Analog Scale (VAS) - Visit 0 vs Visit4 — 53.8; 15.6; 42.4; 11.2 mm
N/A N=45,061 Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
Influenza · Vaccination · Health Promotion
Primary: Flu Vaccination at 2 Weeks After Final Outreach Date — 5798; 5715; 5560; 5583 Participants — p=.054
Phase 3 N=476 A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
Heart Failure
Primary: Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12 — 4.9; 9.2 Score on a scale — p=0.016
Phase 3 N=35 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
Sentinel Lymph Node · Melanoma (Skin) · Breast Cancer
Primary: Number of Participants Where the First, Second and Third Sentinel Nodes Localized With the Use of Fluorescence Imaging Alone — 29; 9; 0 Participants
Phase 4 N=36 Determining the Prognostic Value of Continuous Intrathecal Infusion
Lumbar Post-Laminectomy Syndrome · Chronic Low Back Pain · Vertebral Compression Fracture
Primary: Change in Numerical Rating Scale Pain Scores (NRS) With Activity — 8.40; 8.00; 4.13; 4.19 Score on a scale
Phase 2 N=44 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine
Healthy
Primary: Tolerance to Simulated Hemorrhage — 385; 692 CSI: Cumulative Stress Index
N/A N=12 Intraoperative Neuromonitoring Recording With a Novel SCS Paddle
Chronic Pain · Neuropathic Pain · Failed Back Surgery Syndrome
Primary: Numeric Rating Scale (NRS) — 5.333333333 score on a scale
N/A N=26 Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
Prostate Cancer · Prostate Adenocarcinoma · Radiation Toxicity
Primary: Number of Patients Who Experienced Early Toxicity of SBRT With Integrated Boost for Localized Prostate Cancer — 22 number of participants
N/A N=23 Long Sleep Duration and Vascular Function
Sleep
Primary: Change From Wake in Central Aortic Pulse Pressure After 11 Hours in Bed — -1.5; 0.5 mm Hg — p=0.36
Phase 2 N=124 High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
Hematopoietic Cell Transplantation
Primary: HD-TIV Compared With SD-QIV (Influenza A) - Immunogenicity — 0.62; 0.59; 0.23; 0.25 proportion of participants
Phase 3 N=57 Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
Non Small Cell Lung Cancer · Lung Cancer Stage 1
Primary: Total Morphine Equivalents Consumed — 48; 42.7 MEq
Phase 3 N=166 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
Meniere's Disease
Primary: The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12). — 2.191; 2.415 Definitive Vertigo Day — p=0.623